Clinical Practice Guidelines
Oncotype DX® is included in both the American Society of Clinical Oncology (ASCO) 2007 Update of Recommendations for the Use of
Tumor Markers in Breast Cancer and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
Breast Cancer to identify certain subgroups of patients with node-negative,
estrogen receptor-positive breast cancer who may be successfully treated with
hormonal therapy alone and may not need chemotherapy.
ASCO: The Oncotype DX assay is recommended by the Updated ASCO Clinical Guidelines for Use of Tumor
Markers in Breast Cancer to identify:
- Node-negative, ER-positive breast cancer patients
with low recurrence risk who may not benefit from adjuvant chemotherapy
(specifically CMF/MF)1
- Node-negative, ER-positive breast cancer patients
with high recurrence risk who may derive significant benefit from adjuvant
chemotherapy (specifically CMF/MF)1
NCCN: The National Comprehensive
Cancer Network (NCCN) annually updates their comprehensive clinical practice
guidelines for treatment recommendations relying on evidence based consensus.
The NCCN expert panel recommended in their 2008 Clinical Practice Guidelines
consideration of the use of the Oncotype
DX test for estrogen receptor positive patients with the following clinical
features:
- Tumor size 0.6-1.0cm,
moderate/poorly differentiated or unfavorable features*; or
- Tumor size >1cm
*Unfavorable features: angiolymphatic invasion, high nuclear grade, or high histologic
grade.
For
additional information on guidelines, please click on the following links:
|
 |
|
